This briefing is part of a series on preserving natural capital. Read more:
Safeguarding biodiversity for pharmaceutical innovation costs a fraction of shareholder payouts
Conserving tropical forests could preserve billions of dollars in pharmaceutical value from undiscovered drugs
Key points
- New efforts are underway to create a fair system for accessing and sharing the benefits of nature’s genetic resources, as scientific research shifts from physical samples to digital sequence information (DSI).
- DSI enables companies, particularly pharmaceuticals, biotech and cosmetics, to quickly develop products without physical access. This bypasses the Nagoya Protocol – the first fair access and benefit-sharing framework for genetic information from the Convention on Biological Diversity (CBD) – which relied on physical access to determine the distribution of benefits.
- The Cali Fund, established at the CBD’s COP16 in Cali, Colombia, is a multilateral finance mechanism designed to channel private sector funds toward conserving and sustainably using biodiversity.
- The fund invites companies that benefit from the commercial value of nature’s genetic data to contribute 1% of profits or 0.1% of revenue to help conserve the genetic diversity they rely on and support its custodians. It aims to generate at least USD 1 billion annually.
- The Cali Fund complements the Nagoya Protocol by shifting from transaction-based bilateral agreements to a multilateral approach that reliably channels private sector contributions to where they are needed most.
- The SBI-7 meeting in Nairobi in August 2026 advanced negotiations on the Cali Fund’s operational arrangements, with October’s COP17 set to decide contribution thresholds and rates, fund allocation, effectiveness review and additional measures to improve benefit-sharing and transparency.
International protocols aim to make the use of nature’s valuable genetic resources fair
Bioprospecting is the exploration of ecological habitats and biodiversity for natural products of commercial or social value. The pharmaceutical industry and scientific research engage in bioprospecting, as do the food, healthcare, agricultural biotechnology, brewing and cosmetics industries.
These efforts can generate billions in value, from pharmaceutical compounds discovered in tropical forests to enzymes for use in food and beverage production.
Bioprospecting has historically transferred genetic and biochemical resources from the biodiversity-rich Global South and concentrated derived profits in the Global North – leaving rural and Indigenous host communities and custodians uncompensated.
This challenge led to the creation of Article 15 of the UN Convention on Biological Diversity (CBD), which recognises state sovereignty over genetic resources and establishes the principle of fair and equitable access and benefit-sharing (ABS).
The CBD’s Nagoya Protocol, which entered into force in October 2014, provides a legal framework to facilitate fair ABS of genetic material. It relies on prior informed consent (PIC) and negotiating mutually agreed terms (MAT) – with full usage disclosure – on a transaction-by-transaction basis before access is granted by a government or community to physical genetic material.
The digitisation of genetic information challenges existing frameworks for sharing nature-derived profits
With the rise of digital sequence information (DSI), the process of bioprospecting for valuable genetic resources has become increasingly digitised.1‘DSI’ is “a placeholder term for which no consensus on a replacement or precise definition exists to date”, according to the Digital Sequence Information on Genetic Resources: Concept, Scope and Current Use – a fact-finding study commissioned at the Convention on Biological Diversity COP14. This dematerialised genetic data, stored in freely available, public databases with vast, cross-referenced datasets, enables rapid scientific advancement.
However, DSI also disconnects access to genetic information from the need to physically access nature, and therefore the permits and rules around using a country’s genetic information. This can even result in slowing down responses to global public health emergencies.2The Nagoya Protocol faces practical challenges in public health emergencies, where negotiating bilateral benefit-sharing agreements and complying with administrative procedures can delay the timely sharing of genetic information.
The Nagoya Protocol anticipated this problem and explicitly predicted3Article 10 of the Nagoya Protocol. the need for an alternative approach.
The Cali Fund modernises the Convention on Biological Diversity’s access and benefit-sharing framework for the digital age
The Cali Fund4The Cali Fund for the Fair and Equitable Sharing of Benefits from the Use of Digital Sequence Information on Genetic Resources (Cali Fund) was created through a series of decisions between COP15 – alongside the Kunming-Montreal Global Biodiversity Framework – and COP16, with the former establishing the core principles and structure for DSI benefit-sharing and the latter setting the operational rules to launch the fund itself. is the first-of-its-kind financial function to redistribute benefits generated from the use of digital sequence information. Launched in February 2025 by the CBD, it is part of a larger multilateral mechanism for fair ABS of both monetary and non-monetary DSI-derived benefits.
Table 1 shows how the Cali Fund operates and fits into the broader CBD mechanism.
Table 1
The Cali Fund shifts away from the Nagoya Protocol’s bilateral approach to biodiversity benefit-sharing. Instead of negotiating access and benefits on a transaction-by-transaction basis, it introduces a multilateral system intended to reduce administrative burdens, support open science and improve equity for Indigenous Peoples and Local Communities (IPLCs).
Table 2 shows how the Cali Fund improves on many of the operational challenges of the Nagoya Protocol.
Table 2
The Cali Fund could play a role in closing the biodiversity finance gap
The Cali Fund aims to mobilise biodiversity finance using DSI-related contributions from profit-making companies to help reach the CBD’s USD 200-billion-a-year target for biodiversity by 2030 – part of closing the USD 700 billion annual global biodiversity finance gap.
Currently, the call for private sector contributions is voluntary – companies that rely on DSI are invited to put in 1% of their profits or 0.1% of their revenues. The fund aims to reliably channel resources to the conservation efforts of biodiversity-rich countries, with at least 50% distributed in support of the self-identified needs of Indigenous Peoples and local communities. This will contribute to the implementation of the Kunming-Montreal Global Biodiversity Framework to halt and reverse the loss of biodiversity by 2030.
By August 2026, the fund received only USD 6,000 from two private sector contributors. However, a June 2026 study published by The London School of Economics’ (LSE) Grantham Institute reported that the Cali Fund has the potential to generate an annual revenue of around USD 0.9 billion under realistic voluntary uptake, to around USD 3.6 billion under a full-compliance scenario.5If all 21,690 eligible commercial entities across 100 CBD Party jurisdictions participate, the fund has a maximum annual revenue potential of USD 3.6 billion. As the fund cannot legally compel private companies to contribute, government support through national measures is encouraged to incentivise uptake. Slow early adoption of the Cali Fund by corporations could undercut the fund’s anticipated 10-year revenues by nearly USD 4 billion.
The CBD and a Steering Group for the Cali Fund have spent the last year establishing the basic infrastructure required for a new multilateral finance mechanism, including governance, distribution pathways, allocation methodology and accountability systems.. Major decisions are expected at October’s COP17 in Armenia, which could provide firmer ground for companies to commit funding.
Key decisions set for COP17 will operationalise the Cali Fund
Critical decisions for the CBD at COP17 to finalise the Cali Fund include:
- Formally establish the final corporate size thresholds and payment contribution rates for companies subject to the Cali Fund. The Cali Fund’s success relies almost entirely on a small number of large multinational companies, according to the LSE study – increasing the number of companies expected to contribute by 66% would only increase the fund’s total revenue by 5.5%.
- Decide on an official formula used to distribute funds from the Cali Fund based on biodiversity richness, geographical origin of genetic data and capacity needs.6An Ad Hoc Technical Expert Group is developing the formula. The design of distribution is critical, as the LSE study also points out. For example, designing allocation by country of origin could result in Canada capturing much of the wealth in the Cali Fund, despite lower need.
- Adopt a formal methodology to review the Cali Fund’s effectiveness.7The Steering Committee was responsible for developing this methodology.
- Consider additional modalities for fair and equitable ABS of genetic information under the multilateral mechanism, including taking products and services into account, and the possibility of tools, such as databases, to make DSI available with improved transparency and accountability.
SBI-7 follow-up will finalise fund recommendations ready for COP17
These remaining decisions were discussed and debated at the seventh meeting of the CBD’s Subsidiary Body on Implementation (SBI-7) in Nairobi in August 2026, where the official draft recommendation on Digital Sequence Information on Genetic Resources was submitted to be decided on at COP17.
A contact group, co-chaired by Ida Hellmark (Norway) and Nneka Nicholas (Antigua and Barbuda), was established at the meeting to negotiate and draft the final recommendation for presentation at COP17 in October.
The SBI reviewed several major studies and syntheses of views in formulating its draft recommendation, detailing the steps to operationalise the Cali Fund. These include:
- A study on tools to improve transparency and accountability of DSI access. Following calls from developing nations highlighting methodological shortcomings, conflicts of interest and a lack of solutions to the inequitable status quo, the SBI requested that this study’s findings and recommendations undergo an open peer-review process, to be reviewed at SBI-8 and considered at COP18.
- The methodology for reviewing the effectiveness of the CBD’s multilateral mechanism and the Cali Fund. This calls for an assessment of effectiveness across five enabling conditions and six evaluation pillars, covering financial contributions, benefit-sharing, database compliance, policy coherence, IPLC rights and fiduciary governance. It plans to prioritise the evaluation of structural barriers, such as legal uncertainty or insufficient domestic implementation. This methodology will either be noted or adopted at COP17, and the First Review of Cali Fund Effectiveness is to be presented at COP18.
- Additional modalities to improve fair and equitable ABS under the mechanism. Particularly, how to reduce disproportionate burdens on smaller DSI users created by a flat, sector-wide contribution rate, including a potential products- and services-based contribution pathway. Two options were presented to explore this: a feasibility study and/or an ad hoc open-ended working group to develop the product-based model. It was noted that this discussion on modalities “proved most divergent.” These options will be debated and decided at COP17, and a final decision on additional modalities is to be considered and taken at COP18 or COP19.
In addition, the draft recommendation calls for greater transparency around the Cali Fund’s administrative arrangements, including a review of the MOU at COP17, and an agreement on the Steering Committee nomination process, with members likely to be nominated directly by their respective regional groups.
COP17 will also decide whether governments and database-hosting organisations should submit reports by COP18 on how they have enhanced their databases to comply with the multilateral mechanism.